The North-Western Italian experience with anti IL-5 therapy amd comparison with regulatory trials

BACKGROUND: The severe forms of asthma represent a major burden, because of severity of symptoms, costs and impact on everyday life. Recently, Mepolizumab (MEP) was approved and marketed for the treatment of hypereosinophilic severe asthma. This anti-IL-5 monoclonal antibody reduced exacerbation rat...

Descripción completa

Detalles Bibliográficos
Autores principales: Bagnasco, Diego, Milanese, Manlio, Rolla, Giovanni, Lombardi, Carlo, Bucca, Caterina, Heffler, Enrico, Canonica, Giorgio Walter, Passalacqua, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282342/
https://www.ncbi.nlm.nih.gov/pubmed/30555618
http://dx.doi.org/10.1186/s40413-018-0210-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282342/
https://www.ncbi.nlm.nih.gov/pubmed/30555618
http://dx.doi.org/10.1186/s40413-018-0210-7

Ejemplares similares